CARLSBAD, Calif., July 6 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) announced today it has received notification of the termination
by Agouron Pharmaceuticals, Inc. (a Pfizer company) of the continued
development and commercialization of REMUNE(TM) (HIV-1 Immunogen), an
investigational immune-based therapy for the treatment of individuals infected
with HIV. The Company will regain full rights in the U.S., Europe, Japan and
certain other countries to REMUNE as a result of Agouron's decision to end the
collaboration. Agouron has advised that it will cooperate with the Company to
effect an orderly transition of Agouron's development responsibilities to the
Company.
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted non-viral delivery technology
for gene therapy, which is designed to enable the delivery of genes directly
to the liver via intravenous injection.
Company information can also be located on the Internet Web Site:
http://www.imnr.com.
This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether clinical trials will be successfully
concluded and whether a product will be approved for marketing or be
successfully commercialized. Those factors are discussed more thoroughly in
The Immune Response Corporation's SEC filings, including but not limited to
its report on Form 10-K for the year ended December 31, 2000 and subsequent
Form 10-Q. The Company undertakes no obligation to publicly release the
result of any revisions to these forward-looking statements which may be made
to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
REMUNE(TM) is a trademark of The Immune Response Corporation.
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
Company News On-Call:
http://www.prnewswire.com/comp/434675.html
CONTACT:
Investors, Kathy Lane, 760-771-2236, or
Media, Laura Hansen, Ph.D., 858-860-0266, both for The Immune
Response Corporation
|
